Cagrilintide

Phase 1 Studies: First-in-human studies established the pharmacokinetic profile supporting once-weekly dosing (half-life ~159 hours), dose-proportional exposure, and an acceptable safety profile, with early appetite-suppression and weight-loss signals at higher doses.

Phase 2 Monotherapy Trial - cagrilintide alone (Lau et al., 2021): A multicentre, randomised, double-blind, placebo- and active-controlled (liraglutide 3.0 mg) dose-finding trial in 706 adults with overweight/obesity (BMI >=30, or >=27 with hypertension or dyslipidaemia), without diabetes. Once-weekly cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg vs once-daily liraglutide 3.0 mg vs placebo over 26 weeks (NCT03856047).

Key findings (Lau et al., 2021):

• All cagrilintide doses produced greater weight loss than placebo: 6.0%-10.8% across the 0.3-4.5 mg range vs 3.0% for placebo (trial-product estimand)
• Cagrilintide 4.5 mg: 10.8% vs liraglutide 3.0 mg 9.0% (treatment difference 1.8%, p=0.03)
• Clear dose-response established
• Gastrointestinal adverse events were most common: 41%-63% across cagrilintide doses vs 32% placebo; nausea 20%-47% vs 18% placebo
• Most GI events were mild-to-moderate

Phase 1b Combination Trial - CagriSema (Enebo et al., 2021): The first trial of cagrilintide + semaglutide. A randomised, placebo-controlled, multiple-ascending-dose Phase 1b trial in 96 adults with BMI 27.0-39.9 who were otherwise healthy. Once-weekly cagrilintide (0.16-4.5 mg) or placebo, each in combination with once-weekly semaglutide 2.4 mg, co-escalated over 16 weeks then treated at target dose for 4 weeks (20-week treatment period; NCT03600480). Note: every participant received semaglutide 2.4 mg - there was no cagrilintide-monotherapy arm and no drug-free placebo arm.

Key findings (Enebo et al., 2021):

• At week 20, cagrilintide 2.4 mg + semaglutide 2.4 mg: 17.1% weight loss vs 9.8% for pooled placebo + semaglutide 2.4 mg (estimated treatment difference 7.4%)
• Cagrilintide 1.2 mg + semaglutide: 15.7%; cagrilintide 4.5 mg + semaglutide: 15.4% vs 8.0% matched placebo + semaglutide
• Cagrilintide half-life 159-195 h; cagrilintide did not affect semaglutide exposure or elimination
• Combination was well tolerated; GI disorders were the most common adverse events

Phase 3 REDEFINE Program (CagriSema 2.4 mg / 2.4 mg once weekly):

• REDEFINE 1: adults with overweight/obesity without diabetes, 68 weeks (NCT05567796)
• REDEFINE 2: adults with overweight/obesity and type 2 diabetes, 68 weeks (NCT05394519)
• REDEFINE 3: cardiovascular outcomes
• REDEFINE 4: head-to-head vs tirzepatide

REDEFINE 1 (Garvey et al., 2025): 3417 adults. Mean weight change at 68 weeks was 20.4% with CagriSema vs 3.0% with placebo (treatment-policy/intention-to-treat estimand; estimated difference 17.3 percentage points, p<0.001); the trial-product ("if adherent") estimand was reported at ~22.7% in the topline release. GI adverse events affected 79.6% vs 39.9% with placebo, mostly transient and mild-to-moderate. The 20.4% result - a strong absolute effect - landed below the >25% figures some had projected from earlier-phase data, driving a notable Novo Nordisk stock reaction despite robust efficacy.

REDEFINE 2 (Davies et al., 2025): 1206 adults with obesity and type 2 diabetes. Mean weight change at 68 weeks was 13.7% with CagriSema vs 3.4% placebo (difference 10.4 percentage points, p<0.001); 73.5% reached HbA1c <=6.5% vs 15.9% placebo. GI adverse events affected 72.5% vs 34.4%.

Comparison with Competitors:

Amycretin - Next-Generation Candidate: Novo Nordisk is also developing amycretin, a single-molecule dual GLP-1/amylin agonist, in both oral and injectable forms. Early-phase data have been encouraging (oral amycretin showed roughly 13% weight loss at 12 weeks in Phase 1). If successful, it could offer a single-molecule alternative to the two-injection CagriSema.

Clinical Readouts Pending:

• Cardiovascular outcomes (REDEFINE 3)
• Head-to-head vs tirzepatide (REDEFINE 4)
• Longer-term maintenance of weight loss and weight-regain profile

Regulatory Path: With the Phase 3 REDEFINE program reporting, Novo Nordisk has moved toward regulatory submission for CagriSema. It is not yet FDA-approved. Approval would make CagriSema the first amylin-containing weight-management therapy with efficacy competitive with tirzepatide.

Most Common Side Effects (from trials):

Gastrointestinal (dose-dependent):

• Nausea: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing
• Vomiting: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss
• Diarrhea: moderate frequency
• Constipation: less common than with semaglutide
• Decreased appetite: expected and desired effect; can become problematic if excessive
• Dyspepsia / abdominal discomfort: moderate frequency
• Early satiety: expected effect, sometimes extreme

Metabolic Effects:

• Fatigue: modest, especially during rapid weight loss
• Headache: mild-to-moderate, transient
• Dizziness: especially in dehydrated individuals or with rapid dose escalation
• Injection site reactions: mild, transient

CagriSema-Specific Considerations: When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate.

Rare Serious Adverse Events:

• Pancreatitis: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required
• Gallbladder disease: elevated risk during rapid weight loss (common with any weight-loss drug)
• Hypoglycemia: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients

Amylin-Specific Considerations:

Amyloidogenicity Concerns: Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration.

Calcitonin Receptor Effects: Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about:

• Thyroid C-cell effects (as with GLP-1 agonists)
• Calcium/phosphate homeostasis (calcitonin's native role)

Trials to date have not shown clinically meaningful effects in these domains.

Thyroid C-Cell Tumors: Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide.

Specific Populations:

Pregnancy: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception.

Elderly: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss.

Renal Impairment: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates.

Hepatic Impairment: Limited data; exercise caution in severe hepatic dysfunction.

Children/Adolescents: Not yet studied; pediatric obesity trials may follow adult approval.

Red Flags Requiring Discontinuation:

• Severe persistent nausea/vomiting unresponsive to supportive care
• Signs of pancreatitis (severe abdominal pain radiating to back)
• Signs of gallbladder disease (RUQ pain, jaundice)
• Signs of hypoglycemia requiring rescue (especially in diabetic patients)
• Psychiatric symptoms: significant mood changes
• Severe injection site reactions
• Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness)

Long-Term Safety: As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for:

• Cancer signals (particularly thyroid)
• Cardiovascular outcomes
• Psychiatric effects
• Weight regain trajectory after discontinuation
• Effects on lean muscle mass

Comparison with Other Weight-Loss Drugs:

Cagrilintide (and by extension CagriSema) appears to have:

• Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism)
• Better than liraglutide for convenience (once weekly vs daily)
• Less long-term data than liraglutide, semaglutide, or tirzepatide

Context: CagriSema is not yet FDA-approved (as of April 2026 — Phase 3 REDEFINE program complete, approval expected 2025-2026). This beginner protocol assumes either clinical trial enrollment, off-label compounded cagrilintide + semaglutide use, or early commercial availability.

Preparation Phase (Weeks -2 to 0):

• Confirm BMI ≥27 (with comorbidities) or ≥30 for obesity indication
• Baseline labs: HbA1c, lipid panel, liver enzymes, TSH, testosterone (men), basic metabolic panel
• Body composition baseline: DEXA scan (preferred) or impedance analysis
• Medical history review: pancreatitis history, thyroid disease (MTC/MEN2 contraindicated), family history of thyroid cancer
• Mental health screening: eating disorder history, depression
• Weight history documentation
• Discuss realistic expectations (20-22% weight loss at 68 weeks is the high end)

Beginner Protocol (Weeks 1-16):

CagriSema Initiation:

• Week 1-4: Semaglutide 0.25 mg SC weekly + Cagrilintide 0.3 mg SC weekly
• Week 5-8: Semaglutide 0.5 mg SC weekly + Cagrilintide 0.6 mg SC weekly
• Week 9-12: Semaglutide 1.0 mg SC weekly + Cagrilintide 1.2 mg SC weekly
• Week 13-16: Semaglutide 1.7 mg SC weekly + Cagrilintide 2.4 mg SC weekly
• Week 17+: Semaglutide 2.4 mg + Cagrilintide 2.4 mg (full dose)

Injection Timing:

• Same day each week (typically Sunday or Monday)
• Two separate injections (semaglutide and cagrilintide) — cannot be pre-mixed in same syringe
• Can be same injection site area or different
• Rotate sites to prevent irritation

Administration:

• Subcutaneous injection
• Abdomen, thigh, or upper arm
• 29-31G insulin syringes (5/16" or 1/2")
• Clean site, inject slowly, brief pressure after
• Dispose needle in sharps container

Dietary Guidance:

• Eat smaller portions — appetite will be significantly reduced
• Prioritize protein: 1.6-2.0 g/kg ideal body weight to preserve lean mass
• Adequate hydration: 2-3 L water daily
• Moderate carbohydrate intake
• Avoid late-night eating (gastric emptying already slowed)
• Multivitamin supplementation

Exercise Guidance:

• Resistance training 2-3x weekly: preserve lean muscle mass during rapid weight loss
• Compound movements: squats, deadlifts, presses, pulls
• Progressive overload approach
• Adequate recovery (weight loss is a stressor)
• Cardiovascular: 150 min/week moderate OR 75 min/week vigorous

Weeks 1-4 Expectations:

• Initial GI side effects likely: nausea, appetite suppression, early satiety
• Weight loss: typically 2-4% of body weight
• Fatigue, especially with rapid weight loss
• Mild dehydration risk

Weeks 5-12 Expectations:

• GI tolerance improves
• Weight loss continues: typically 4-8% by week 12
• Energy typically normalizes
• Ongoing titration requires patience

Week 16 Decision Points:

• If full dose tolerated and weight loss on track: continue to intermediate protocol
• If ongoing GI symptoms limiting dose: maintain current dose longer before escalating
• If plateau: reassess calorie intake, exercise, adherence
• If intolerable side effects: reduce dose or switch therapy

Monitoring:

• Weekly: body weight, blood pressure, subjective symptoms
• Month 1: clinical check-in, adjust titration as needed
• Month 3: comprehensive labs + body composition
• Month 6: comprehensive labs + body composition + DEXA

Red Flags Requiring Medical Attention:

• Severe persistent nausea/vomiting with dehydration
• Severe abdominal pain (pancreatitis concern)
• Symptoms suggestive of gallbladder disease
• Severe fatigue beyond expected
• Mood changes or depression
• Any signs of hypoglycemia (especially if diabetic)
• Neck mass or thyroid-related symptoms

What Beginner Protocol Does NOT Cover:

• Maintenance dosing after initial 6-12 month weight loss phase
• Management of weight regain after discontinuation
• Pediatric use
• Pregnancy (contraindicated)
• Complex diabetic management (requires endocrinology co-management)

For users who have completed 16+ weeks of titration successfully and want to optimize long-term weight loss maintenance.

Intermediate Protocol (Months 4-12):

Full Maintenance Dose:

• Semaglutide 2.4 mg SC weekly
• Cagrilintide 2.4 mg SC weekly
• Consistent weekly schedule
• Most weight loss occurs in this phase

Optimization Strategies:

Protein Optimization:

• 1.6-2.0 g/kg ideal body weight daily
• Distribute across 3-4 meals (20-40 g per meal)
• Leucine-rich sources preferred (dairy, meat, whey)
• Consider whey protein supplementation if intake falls short

Resistance Training Progression:

• Progressive overload essential
• 3-4 sessions weekly during stable dosing phase
• Compound movements prioritized
• Track strength metrics (not just weight)
• Consider personal trainer or structured program

Cardiovascular Exercise:

• 150 minutes moderate-intensity OR 75 minutes vigorous weekly
• HIIT 1-2x weekly for metabolic benefits
• Walking for active recovery
• Avoid overtraining (rest is part of program)

Nutritional Quality:

• Whole food emphasis
• Adequate fiber (25-35 g daily)
• Fatty fish 2x weekly for omega-3
• Abundant vegetables for micronutrients
• Limit ultra-processed foods

Sleep Optimization:

• 7-9 hours nightly
• Consistent sleep/wake schedule
• Appropriate sleep environment
• Address sleep apnea if present (weight loss may improve)

Stress Management:

• Chronic stress impairs weight loss
• Meditation, mindfulness, or therapy as appropriate
• Social support for eating behavior changes
• Address underlying emotional eating

Hormonal Monitoring:

Thyroid:

• TSH, free T4 every 6 months
• Weight loss may alter thyroid needs
• Adjust replacement as needed

HPG Axis:

• Men: testosterone every 6 months during rapid weight loss
• Women: menstrual tracking; if amenorrhea develops, consult reproductive endocrinology
• Significant weight loss can suppress HPG axis via leptin reduction

Metabolic Markers:

• HbA1c every 3-6 months
• Lipid panel every 3-6 months
• Liver enzymes quarterly initially
• Kidney function annually

Body Composition:

• DEXA every 6 months (gold standard)
• Track lean mass, fat mass, visceral adipose tissue
• Target: preserve or minimize lean mass loss during weight loss
• Redistribute if lean mass dropping excessively (increase protein, resistance training)

Common Intermediate Phase Issues:

Plateau (months 6-9):

• Expected for most patients around 40-50% of total expected weight loss
• Reassess caloric intake (may need adjustment)
• Reassess activity levels
• Check adherence to injections
• Consider adding resistance training if not already

Decreased Appetite Extremes:

• If inadequate caloric intake threatens lean mass: prioritize protein
• Structured meal timing despite low hunger
• Consider temporary dose reduction if severe

Lean Mass Loss:

• Monitor via DEXA
• Intervene: increase protein, intensify resistance training
• Consider GH peptides (Sermorelin, CJC-1295/Ipamorelin) if significant
• Slow rate of weight loss if needed

Expected Trajectory:

• Month 6: 10-15% weight loss typical
• Month 9: 15-20% weight loss typical
• Month 12: 18-22% weight loss typical (matches REDEFINE 1 landmark cohort)
• Month 18: plateau approaches typical nadir

Side Effect Management:

Persistent GI Issues:

• Usually improve with time
• Split injection or timing changes don't affect weekly drugs
• Ondansetron for persistent nausea (physician guidance)
• Eat smaller, more frequent meals

Fatigue:

• Ensure adequate calories (not excessive deficit)
• Adequate sleep
• Iron studies if persistent
• Thyroid status check

Hair Loss:

• Common during rapid weight loss
• Usually resolves when weight stabilizes
• Adequate protein, zinc, biotin
• Genetics a factor

Quality of Life Monitoring:

• Energy levels
• Mood and mental health
• Social eating situations
• Body image (positive and negative)
• Sleep quality
• Sexual function

Partner/Family Support:

• Education on weight-loss drugs
• Eating pattern changes
• Support for new lifestyle
• Joint meal planning

When to Consider Transition:

Progress to Advanced Protocol:

• After 12-18 months of successful weight loss
• Stable lifestyle habits established
• Addressing long-term maintenance

Modify Approach:

• If progress stalls >3 months
• If side effects become intolerable
• If complex medical issues develop

Reduce Dose:

• After reaching target weight
• If lean mass loss excessive
• Part of maintenance planning

Discontinue:

• Target weight achieved with stable lifestyle
• Medical necessity
• Insurance coverage issues
• Personal choice
• Always with maintenance plan to prevent regain

For experienced users approaching or maintaining target weight, typically 12-24+ months into therapy.

Advanced Use Case 1: Maintenance After Weight Loss Goal Achievement

Scenario: Target weight reached, transitioning to long-term maintenance.

Protocol Options:

Option A: Continued Full Dose Maintenance

• Continue CagriSema 2.4 mg + 2.4 mg weekly
• Rationale: strongest evidence for preventing regain
• Drawback: ongoing cost and side effects

Option B: Reduced Maintenance Dose

• CagriSema 1.2 mg + 1.2 mg weekly (half dose)
• Some clinical evidence for maintenance at lower doses
• Balance: cost, convenience, prevention of regain

Option C: Semaglutide Alone Maintenance

• Discontinue cagrilintide, continue semaglutide 2.4 mg weekly
• Rationale: leverage established GLP-1 monotherapy maintenance data
• Concern: may see some regain vs dual therapy

Option D: Gradual Discontinuation

• Taper both drugs over 6-12 months
• Intensive lifestyle reinforcement
• Expect some regain (average ~50% of lost weight over 1-2 years post-discontinuation based on other weight-loss drug data)

Advanced Use Case 2: Weight Regain After Discontinuation

Scenario: Patient discontinued CagriSema, now regaining.

Protocol:

• Reassess readiness and realistic goals
• Re-initiate CagriSema with titration (may be faster titration given prior exposure)
• Lifestyle intervention intensification
• Consider behavioral therapy
• Address underlying factors (stress, sleep, medications)

Advanced Use Case 3: Aggressive Weight Loss + Body Recomposition

Scenario: Beyond standard weight loss — targeting specific body composition.

Protocol:

• CagriSema 2.4 mg + 2.4 mg weekly
• Intensive resistance training (4-5x weekly)
• Protein 2.0+ g/kg ideal body weight
• Monitoring: DEXA every 3 months
• Optional: GH peptides (Tesamorelin for visceral fat, CJC-1295/Ipamorelin for lean mass support)
• HPG axis monitoring and support if needed
• Medical oversight recommended

Advanced Use Case 4: Diabetic Patient Optimization

Scenario: Type 2 diabetes with obesity, seeking glycemic and weight control.

Protocol:

• CagriSema 2.4 mg + 2.4 mg weekly
• Monitor HbA1c monthly during initiation
• Reduce insulin/sulfonylurea doses proactively (hypoglycemia risk)
• Coordinate with endocrinology
• May be able to discontinue some diabetes medications
• Target: HbA1c <7.0% and meaningful weight loss

Advanced Use Case 5: Post-Bariatric Surgery Patient

Scenario: Post-bariatric regain or inadequate response.

Protocol:

• CagriSema 2.4 mg + 2.4 mg weekly
• Careful monitoring for GI effects (altered anatomy)
• Adjust based on tolerance
• Multivitamin/mineral supplementation (bariatric-appropriate)
• Medical oversight essential
• May need lower doses than non-bariatric patients

Complex Monitoring for Advanced Protocols:

• Quarterly comprehensive labs
• DEXA every 3-6 months
• Thyroid panel every 6 months
• HPG axis every 6 months
• Cardiovascular assessment annually
• Mental health screening ongoing
• Quality of life measures

Integration with Multi-Peptide Protocols:

With GH Axis:

• Tesamorelin for visceral fat reduction (evidence-based in HIV lipodystrophy)
• Sermorelin or CJC-1295/Ipamorelin for lean mass preservation
• Timing: GH peptides evening, CagriSema any weekly time

With Reproductive Axis:

• Gonadorelin or HCG for men with rapid testosterone decline
• Enclomiphene for long-term HPG maintenance
• Reproductive endocrinology for women with amenorrhea

With Repair/Recovery:

• BPC-157, TB-500 for joint/tissue during increased activity
• Thymosin-beta-4 family peptides
• Timing: independent of CagriSema

Long-Term Safety Surveillance:

• Annual thyroid ultrasound if concerning history
• Lifetime monitoring for pancreatitis signs
• Gallbladder assessment if symptoms
• Mental health vigilance
• Cancer screening age-appropriate

When to Consult Specialist:

• Endocrinology: complex diabetes, thyroid abnormalities
• Bariatric medicine: post-surgery or resistant cases
• Cardiology: cardiovascular disease
• Psychiatry: mental health concerns
• Reproductive endocrinology: fertility issues
• Oncology: concerning signs or findings

Quality of Life Optimization:

• Social eating strategies
• Travel planning (refrigeration, time zones)
• Stress management long-term
• Partner/family involvement
• Professional support (therapist, dietitian, trainer)